Medivation (MDVN) : 14 analysts are covering Medivation (MDVN) and their average rating on the stock is 2.57, which is read as a Hold. 3 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. A total of 11 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.
Medivation (MDVN) : Average target price received by Medivation (MDVN) is $71.82 with an expected standard deviation of $12.35. The most aggressive target on the stock is $82, whereas the most downbeat target is $40. 14 financial analysts are currently covering the stock.
Also, Citigroup downgrades their rating on the shares of Medivation (NASDAQ:MDVN). The current rating of the shares is Hold. Earlier, the shares were rated a Buy by the brokerage firm. Equity Analysts at the Firm raises the price target to $81.5 per share from $73 per share. The rating by the firm was issued on August 23, 2016.
Medivation (NASDAQ:MDVN): The stock opened in the green at $81.07 on Thursday, but the bulls found it difficult to push the prices higher. The stock reached a high of $81.15 and a low of $81.02 for the day. The stock did not find buyers even at the lows and closed at $81.05 recording a loss of -0.09%. 5,646,157 shares exchanged hands during the trading day. The stock had closed at $81.12 in the previous days trading.
Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma, Inc. has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe, and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab, an immune modulatory, anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech, Ltd.